MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.
You may also be interested in...
Medicare Anti-VEGF Evaluation: TA Notes Safety Comparison Challenges For Avastin, Cost-Benefit Data
The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.
Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012
Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough
Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.